NVX-412, a New Oncology Drug Candidate, Induces S-Phase Arrest and DNA Damage in Cancer Cells in a p53-Independent Manner

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Hebar, Alexandra ^a   Rütgen, Barbara C ^b   Selzer, Edgar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NVX 412; PROTEIN P53; PYRAZINE 2 CARBOXYLIC ACID N' (7 FLUORO PYRROLO[1,2 ALPHA]QUINOXALIN 4 YL)HYDRAZIDE OXALIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; S PHASE CELL CYCLE CHECKPOINT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SHAPE; CELL SIZE; DNA DAMAGE; DNA REPLICATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDRAZINES; INHIBITORY CONCENTRATION 50; NEOPLASMS; PHOSPHORYLATION; QUINOXALINES; S PHASE CELL CYCLE CHECKPOINTS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866433643     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045015     Document Type: Article

References (36)

1. WHO (2011) Causes of Death 2008, Summary Tables.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
3. Grande F, Aiello F, Grazia OD, Brizzi A, Garofalo A, et al. (2007) Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem 15: 288-294.
4. Aakeroy CB, Fasulo ME, Desper J, (2007) Cocrystal or salt: does it really matter? Mol Pharm 4: 317-322.
5. Shoemaker RH, (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
6. Rütgen BC, Hammer SE, Gerner W, Christian M, de Arespacochaga AG, et al. (2010) Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res 34: 932-938.
7. Kisseberth WC, Nadella MV, Breen M, Thomas R, Duke SE, et al. (2007) A novel canine lymphoma cell line: a translational and comparative model for lymphoma research. Leuk Res 31: 1709-1720.
8. Momoi Y, Okai Y, Watari T, Goitsuka R, Tsujimoto H, et al. (1997) Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Vet Immunol Immunopathol 59: 11-20.
9. Nakaichi M, Taura Y, Kanki M, Mamba K, Momoi Y, et al. (1996) Establishment and characterization of a new canine B-cell leukemia cell line. J Vet Med Sci 58: 469-471.
10. Dolstra H, Fredrix H, Maas F, Coulie PG, Brasseur F, et al. (1999) A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 189: 301-308.
11. Liu M, Taketani T, Li R, Takita J, Taki T, et al. (2001) Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leuk Res 25: 441-447.
12. Andersson A, Eden P, Lindgren D, Nilsson J, Lassen C, et al. (2005) Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia 19: 1042-1050.
13. Rucker FG, Sander S, Dohner K, Dohner H, Pollack JR, et al. (2006) Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations. Leukemia 20: 994-1001.
14. Furley AJ, Reeves BR, Mizutani S, Altass LJ, Watt SM, et al. (1986) Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines. Blood 68: 1101-1107.
15. Lamore SD, Wondrak GT, (2012) Autophagic-lysosomal dysregulation downstream of cathepsin B inactivation in human skin fibroblasts exposed to UVA. Photochem Photobiol Sci 11: 163-172.
16. Reyes-Reyes EM, Teng Y, Bates PJ, (2010) A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res 70: 8617-8629.
17. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, et al. (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59.
18. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C, (2006) Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319.
19. Lacroix M, Toillon RA, Leclercq G, (2006) p53 and breast cancer, an update. Endocr Relat Cancer 13: 293-325.
20. Vazquez A, Bond EE, Levine AJ, Bond GL, (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
21. Campisi J, d'Adda di Fagagna F, (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740.
22. Dolznig H, Grebien F, Sauer T, Beug H, Mullner EW, (2004) Evidence for a size-sensing mechanism in animal cells. Nat Cell Biol 6: 899-905.
23. Havens CG, Ho A, Yoshioka N, Dowdy SF, (2006) Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol Cell Biol 26: 4701-4711.
24. Barberis M, Klipp E, Vanoni M, Alberghina L, (2007) Cell size at S phase initiation: an emergent property of the G1/S network. PLoS Comput Biol 3: e64.
25. Goto H, Izawa I, Li P, Inagaki M (2012) Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? Cancer Sci.
26. van Attikum H, Gasser SM, (2005) The histone code at DNA breaks: a guide to repair? Nat Rev Mol Cell Biol 6: 757-765.
27. Ward IM, Chen J, (2001) Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 276: 47759-47762.
28. Ewald B, Sampath D, Plunkett W, (2007) H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 6: 1239-1248.
29. Avemann K, Knippers R, Koller T, Sogo JM, (1988) Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol Cell Biol 8: 3026-3034.
30. Pommier Y, (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802.
31. Bartek J, Lukas C, Lukas J, (2004) Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5: 792-804.
32. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
33. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, et al. (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6: 50-56.
34. Gasco M, Crook T, (2003) p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat 6: 323-328.
35. Arya AK, El-Fert A, Devling T, Eccles RM, Aslam MA, et al. (2010) Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br J Cancer 103: 186-195.
36. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.